Combination of oral temozolomide and etoposide as palliative chemotherapy for recurrent or progressive neuroblastoma
We retrospectively analyzed the clinical outcomes of seven patients receiving palliative treatment with oraltemozolomide (TMZ)/etoposide (ETP) for recurrent or progressive neuroblastoma (NB). Patients received a median of three cycles of TMZ/ETP. One patient achieved complete response (CR), three showed stable disease, and three showed progressive disease. The median time to progression in the six patients without achieving CR was 82 days excluding one achieving CR for >222 days. Grade 3 hematological toxicities were common but manageable, and no patients experienced severe non-hematological toxicity. TMZ/ETP is a feasible palliative chemotherapy option for certain patients with recurrent or progressive NB.
Authors
- Katsutsugu Umeda
- Junko Takita
- Shuro Nishio (ORCID: https://orcid.org/0009-0007-2200-4685)
- Hirokazu Kobushi
- H Hiramatsu
- Kimiyoshi Sakaguchi (ORCID: https://orcid.org/0000-0002-3665-401X)
- Elena Yukie Uebayashi (ORCID: https://orcid.org/0000-0003-3906-6560)
- Satoshi Saida (ORCID: https://orcid.org/0000-0002-8930-3539)
- Itaru Kato
- Ryo Akazawa (ORCID: https://orcid.org/0000-0002-8770-0493)
- Ikuya Usami
- E.T. Ogawa (ORCID: https://orcid.org/0009-0009-8081-9641)
- Daisuke Fukao
- Hirohito Kubota (ORCID: https://orcid.org/0000-0002-6935-5120)
- Tatsuya Okamoto (ORCID: https://orcid.org/0000-0003-1958-0714)
- Miki Yamamoto
Institutions
- Kyoto University (JP)
- Hamamatsu University School of Medicine (JP)
- Hyogo Prefectural Amagasaki General Medical Center (JP)
- Japanese Red Cross Society Wakayama Medical Center (JP)
- Kindai University (JP)
Publication Details
- Journal
- Pediatric Hematology and Oncology
- Published
- 2026-01-02
- DOI
- https://doi.org/10.1080/08880018.2025.2586674
- Primary Topic
- Neuroblastoma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00